Hyperthermic intracavitary nanoaerosol therapy (HINAT) as an improved approach for pressurised intraperitoneal aerosol chemotherapy (PIPAC): Technical description, experimental validation and first proof of concept

• Daniel Göhler,
• Stephan Große,
• Alexander Bellendorf,
• Thomas Albert Falkenstein,
• Mehdi Ouaissi,
• Jürgen Zieren,
• Michael Stintz and
• Urs Giger-Pabst

Beilstein J. Nanotechnol. 2017, 8, 2729–2740, doi:10.3762/bjnano.8.272

• chemotherapy for the treatment of peritoneal carcinomatosis. However, recent reports reveal limitations of the currently available technology. Material and Methods: A novel approach for pressurised intraperitoneal aerosol chemotherapy (PIPAC), called hyperthermic intracavitary nanoaerosol therapy (HINAT

• nm) unipolar-charged hyperthermic (41 °C) drug aerosol for quasi uniform drug deposition over the whole peritoneum with significantly deeper drug penetration than that offered by conventional PIPAC. Keywords: HINAT; intracavitary; intraperitoneal; nanoaerosol; PIPAC; pressurized; therapy

• severely restricted by physical circumstances and thus only minor improvements are expected. Consequently, we developed an improved PIPAC approach for the treatment of enhanced PC, called hyperthermic intracavitary nanoaerosol therapy (HINAT) that enables an even more homogeneous intracavitary drug